Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Unraveling the Plasmodium vivax sporozoite transcriptional journey from mosquito vector to human host.

Roth A, Adapa SR, Zhang M, Liao X, Saxena V, Goffe R, Li S, Ubalee R, Saggu GS, Pala ZR, Garg S, Davidson S, Jiang RHY, Adams JH.

Sci Rep. 2018 Aug 15;8(1):12183. doi: 10.1038/s41598-018-30713-1.

2.

Recent Advances in the [Fe-S] Cluster Biogenesis (SUF) Pathway Functional in the Apicoplast of Plasmodium.

Pala ZR, Saxena V, Saggu GS, Garg S.

Trends Parasitol. 2018 Sep;34(9):800-809. doi: 10.1016/j.pt.2018.05.010. Epub 2018 Jul 28. Review.

PMID:
30064903
3.

Structural characterization of semi-heusler/light metal composites prepared by spark plasma sintering.

Kopeček J, Bartha K, Mušálek R, Pala Z, Chráska T, Beran P, Ryukhtin V, Strunz P, Nováková J, Stráský J, Novák P, Heczko O, Landa M, Seiner H, Janeček M.

Sci Rep. 2018 Jul 24;8(1):11133. doi: 10.1038/s41598-018-29479-3.

4.

Deciphering the role of IspD (2‑C‑methyl‑D‑erythritol 4‑phosphate cytidyltransferase) enzyme as a potential therapeutic drug target against Plasmodium vivax.

Saggu GS, Garg S, Pala ZR, Kochar SK, Saxena V.

Gene. 2018 Oct 30;675:240-253. doi: 10.1016/j.gene.2018.06.084. Epub 2018 Jun 26.

PMID:
29958953
5.

Characterization of 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (IspG) from Plasmodium vivax and it's potential as an antimalarial drug target.

Saggu GS, Garg S, Pala ZR, Yadav SK, Kochar SK, Kochar DK, Saxena V.

Int J Biol Macromol. 2017 Mar;96:466-473. doi: 10.1016/j.ijbiomac.2016.12.033. Epub 2016 Dec 20.

PMID:
28007455
6.

New Insight into Isoprenoids Biosynthesis Process and Future Prospects for Drug Designing in Plasmodium.

Saggu GS, Pala ZR, Garg S, Saxena V.

Front Microbiol. 2016 Sep 13;7:1421. doi: 10.3389/fmicb.2016.01421. eCollection 2016. Review.

7.

In vitro regeneration and optimization of factors affecting Agrobacterium mediated transformation in Artemisia Pallens, an important medicinal plant.

Alok A, Shukla V, Pala Z, Kumar J, Kudale S, Desai N.

Physiol Mol Biol Plants. 2016 Apr;22(2):261-9. doi: 10.1007/s12298-016-0353-3. Epub 2016 Apr 25.

8.

Structural and functional characterization of an iron-sulfur cluster assembly scaffold protein-SufA from Plasmodium vivax.

Pala ZR, Saxena V, Saggu GS, Yadav SK, Pareek RP, Kochar SK, Kochar DK, Garg S.

Gene. 2016 Jul 1;585(1):159-165. doi: 10.1016/j.gene.2016.03.041. Epub 2016 Mar 28.

PMID:
27033210
9.

Enhanced production of an anti-malarial compound artesunate by hairy root cultures and phytochemical analysis of Artemisia pallens Wall.

Pala Z, Shukla V, Alok A, Kudale S, Desai N.

3 Biotech. 2016 Dec;6(2):182. doi: 10.1007/s13205-016-0496-5. Epub 2016 Aug 27.

10.

Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.

Vlaming ML, van Esch A, van de Steeg E, Pala Z, Wagenaar E, van Tellingen O, Schinkel AH.

Drug Metab Dispos. 2011 Aug;39(8):1338-44. doi: 10.1124/dmd.111.038794. Epub 2011 May 12.

11.

Evaluation of carcinogenic effects of electromagnetic fields (EMF).

Bayazit V, Bayram B, Pala Z, Atan O.

Bosn J Basic Med Sci. 2010 Aug;10(3):245-50. Review. Retraction in: Mehic B. Bosn J Basic Med Sci. 2010 Nov;10(4):331.

12.

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.

Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, van Tellingen O, Schinkel AH.

Mol Cancer Ther. 2009 Dec;8(12):3350-9. doi: 10.1158/1535-7163.MCT-09-0668.

13.

Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.

Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, Schinkel AH.

Clin Cancer Res. 2009 May 1;15(9):3084-93. doi: 10.1158/1078-0432.CCR-08-2940. Epub 2009 Apr 21.

14.

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, Oude Elferink RP, van de Wetering K, Schinkel AH.

Clin Cancer Res. 2008 Dec 15;14(24):8152-60. doi: 10.1158/1078-0432.CCR-08-1609.

Supplemental Content

Support Center